Last updated: 19 August 2019 at 6:25am EST

Ryan Lynch Net Worth




The estimated Net Worth of Ryan Lynch is at least $79.5 Thousand dollars as of 14 September 2017. Ryan Lynch owns over 3,500 units of Concert Pharmaceuticals Inc stock worth over $79,515 and over the last 7 years Ryan sold CNCE stock worth over $0.

Ryan Lynch CNCE stock SEC Form 4 insiders trading

Ryan has made over 1 trades of the Concert Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Ryan exercised 3,500 units of CNCE stock worth $33,110 on 14 September 2017.

The largest trade Ryan's ever made was exercising 3,500 units of Concert Pharmaceuticals Inc stock on 14 September 2017 worth over $33,110. On average, Ryan trades about 500 units every 0 days since 2017. As of 14 September 2017 Ryan still owns at least 9,500 units of Concert Pharmaceuticals Inc stock.

You can see the complete history of Ryan Lynch stock trades at the bottom of the page.



What's Ryan Lynch's mailing address?

Ryan's mailing address filed with the SEC is C/O CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON, MA, 02421.

Insiders trading at Concert Pharmaceuticals Inc

Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V..., and Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.



What does Concert Pharmaceuticals Inc do?

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.



What does Concert Pharmaceuticals Inc's logo look like?

Concert Pharmaceuticals Inc logo

Complete history of Ryan Lynch stock trades at Concert Pharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
14 Sep 2017 Ryan Lynch
PAO
Option 3,500 $9.46 $33,110
14 Sep 2017
9,500


Concert Pharmaceuticals Inc executives and stock owners

Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: